



ALEMBIC PHARMACEUTICALS LIMITED
 Regd. Office: Alembic Road, Vadodara 390 003
 CIN:L24230GJ2010PLC061123
 Ph #:0265 2280550 Fax #: 0265 2282506
 Email : apl.investors@alembic.co.in Website: www.alembic-india.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th September, 2015

Rs. In Lacs

	Particulars	CONSOLIDATED					
		Quarter Ended			Period Ended		Year Ended
		September-15	June-15	September-14	September-15	September-14	March-15
		(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Audited)
1	(a) Net Sales / Income from Operations						
	Domestic	32,549	30,336	32,743	62,885	60,583	117,394
	Exports	69,225	28,696	22,132	97,921	43,905	89,379
	Total	101,774	59,032	54,875	160,806	104,488	206,773
	Less : Excise Duty	990	791	250	1,781	498	1,505
	Net Sales / Income from Operations	100,784	58,241	54,625	159,025	103,990	205,268
	(b) Other Operating Income	92	93	83	185	146	344
	Total Income from Operations	100,876	58,334	54,708	159,210	104,136	205,612
2	Expenses						
	(a) Consumption of Raw Materials & Packing Materials	18,679	15,235	15,501	33,914	30,230	54,049
	(b) Purchase of traded goods	7,840	6,584	7,126	14,424	12,773	24,692
	(c) Decrease/(increase) in stock in trade and work in progress	(3,891)	(498)	(3,660)	(4,389)	(6,337)	(7,289)
	(d) Employees' Cost	11,961	8,784	7,677	20,746	15,238	30,676
	(e) Research and Development Expense	7,796	4,795	3,109	12,590	6,062	12,162
	(f) Other Expenses	20,888	13,228	14,212	34,116	25,828	51,025
	Total Expenses	63,273	48,129	43,965	111,401	83,791	165,315
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	37,603	10,205	10,743	47,809	20,345	40,297
4	Other Income	5	3	14	8	32	230
5	Depreciation	1,327	1,289	1,084	2,617	2,155	4,441
6	Interest (Net)	73	62	104	134	160	178
7	Net Profit from Ordinary Activities before Tax	36,208	8,857	9,569	45,066	18,062	35,908
8	Tax Expense						
	Less : Provision for Current Tax	7,354	1,875	2,136	9,230	3,871	7,635
	Add : MAT Credit Entitlement	488	572	-	1,060	-	739
	Less : Provision for Deferred Tax Liability	488	572	293	1,060	-	739
9	Net Profit from Ordinary Activities after Tax	28,854	6,982	7,226	35,836	14,191	28,273
10	Share of Profit of Associates	35	6	1	41	3	20
11	Net Profit after Tax and share of profit of associates	28,890	6,988	7,227	35,877	14,194	28,293
12	Paid up Equity Share Capital (Face value of share Rs 2/-)	3,770	3,770	3,770	3,770	3,770	3,770
13	Reserves excluding Revaluation Reserve	-	-	-	-	-	84,694
14	Basic & Diluted EPS (Not Annualised)	15.32	3.71	4.10	19.03	7.53	15.01
	PART- II						
A	Particulars of Shareholding						
1	Public Shareholding						
	- Number of Shares	48777294	48777294	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding						
	- Fully Non - Encumbered						
	- Number of Shares	139738620	139738620	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS	Quarter Ended on 30th September, 2015					
	Pending at the beginning of the quarter	NIL					
	Received during the quarter	3					
	Disposed of during the quarter	3					
	Remaining unresolved at the end of the quarter	NIL					

Notes :

1 The above results, have been duly reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors.

2 The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website www.alembic-india.com.

The key information on the standalone financial results are as under:

Rs in Laacs

Particulars	Quarter Ended			Period Ended		Year Ended
	Sep/15	Jun/15	Sep/14	Sep/15	Sep/14	Mar/15
	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Audited)
Net Sales / Income from Operations	92,254	57,486	54,138	149,740	102,318	201,900
Profit Before Tax	32,621	9,505	10,247	42,127	18,402	36,286
Profit After Tax	25,267	7,630	8,405	32,897	14,553	28,661

3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).

4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Pharmaceuticals Limited

Place : Vadodara

Chirayu Amin

Date : 27th October, 2015

Chairman and Managing Director

Visit us at www.alembic-india.com



ALEMBIC PHARMACEUTICALS LIMITED
 Regd. Office: Alembic Road, Vadodara 390 003
 CIN: L24230GJ2010PLC061123
 Ph #: 0265 2280550 Fax #: 0265 2282506
 Email : apl.investors@alembic.co.in Website: www.alembic-india.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th September, 2015

Rs. in lacs

	Particulars	STANDALONE					
		Quarter Ended			Period Ended		Year Ended
		September-15	June-15	September-14	September-15	September-14	March-15
	PART- I	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Audited)
1	(a) Net Sales / Income from Operations						
	Domestic	32,549	30,336	32,743	62,885	60,583	117,394
	Exports	60,603	27,849	21,562	88,452	42,087	85,681
	Total	93,152	58,185	54,305	151,336	102,670	203,075
	Less : Excise Duty	990	791	250	1,781	498	1,505
	Net Sales / Income from Operations	92,162	57,394	54,055	149,555	102,172	201,570
	(b) Other Operating Income	92	92	83	185	146	330
	Total Income from Operations	92,254	57,486	54,138	149,740	102,318	201,900
2	Expenses						
	(a) Consumption of Raw Materials & Packing Materials	18,679	15,235	15,501	33,914	30,229	54,049
	(b) Purchase of traded goods	7,832	6,584	7,127	14,416	12,773	24,663
	(c) Decrease/(increase) in stock in trade and work in progress	(3,891)	(498)	(3,660)	(4,389)	(6,337)	(7,289)
	(d) Employees' Cost	11,474	8,487	7,432	19,961	14,754	29,657
	(e) Research and Development Expense	5,734	4,023	2,770	9,757	5,524	10,903
	(f) Other Expenses	18,433	12,828	13,559	31,260	24,702	49,136
	Total Expenses	58,261	46,659	42,729	104,919	81,645	161,119
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	33,994	10,827	11,409	44,821	20,673	40,781
4	Other Income	5	3	14	8	32	57
5	Depreciation	1,325	1,288	1,084	2,613	2,155	4,441
6	Interest (Net)	53	37	92	89	148	111
7	Net Profit from Ordinary Activities before Tax	32,621	9,505	10,247	42,127	18,402	36,286
8	Tax Expense						
	Less : Provision for Current Tax	7,354	1,875	2,135	9,230	3,849	7,625
	Add : MAT Credit Entitlement	488	572	-	1,060	-	739
	Less : Provision for Deferred Tax Liability	488	572	293	1,060	-	739
9	Net Profit from Ordinary Activities after Tax	25,267	7,630	8,405	32,897	14,553	28,661
10	Paid up Equity Share Capital (Face value of share Rs. 2/-)	3,770	3,770	3,770	3,770	3,770	3,770
11	Reserves excluding Revaluation Reserve	-	-	-	-	-	79,586
12	Basic & Diluted EPS (Not Annualised)	13.40	4.05	4.46	17.45	7.72	15.20
	PART- II						
A	Particulars of Shareholding						
1	Public Shareholding						
	- Number of Shares	48777294	48777294	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding						
	- Fully Non - Encumbered						
	- Number of Shares	139738620	139738620	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS	Quarter Ended on 30th September, 2015					
	Pending at the beginning of the quarter	NIL					
	Received during the quarter	3					
	Disposed of during the quarter	3					
	Remaining unresolved at the end of the quarter	NIL					